Scarica l'app Stockscreener
1.21
0.83%
0.01
Dopo l'orario di chiusura:
1.20
-0.01
-0.83%
Panoramica
Notizia
Cronologia dei prezzi
Catena di opzioni
Financials
Perché LXRX Giù?
Forum
Previsione
Frazionamento azionario
Lexicon Pharmaceuticals Inc Borsa (LXRX) Ultime notizie
Lexicon Pharmaceuticals to Report Second Quarter 2025 Financial Results on August 6, 2025 - The Manila Times
Lexicon Pharmaceuticals Scheduled to Release Q2 2025 Financial Results and Conduct Conference Call on August 6, 2025 - Quiver Quantitative
What drives Lexicon Pharmaceuticals Inc. stock pricePowerful market insights - jammulinksnews.com
Is Lexicon Pharmaceuticals Inc. a good long term investmentUnstoppable profit momentum - jammulinksnews.com
Lexicon Pharmaceuticals Inc. Stock Analysis and ForecastOver 200% growth - jammulinksnews.com
What analysts say about Lexicon Pharmaceuticals Inc. stockTremendous gains - Autocar Professional
H.C. Wainwright Reiterates a Buy Rating on Lexicon Pharmaceuticals (LXRX) - MSN
Lexicon Pharmaceuticals: A High-Potential Biotech Play in the Diabetes Space - AInvest
10 Hot Penny Stocks to Invest in Now - Insider Monkey
Lexicon to Present Patient-reported Data on Diabetic Peripheral Neuropathic Pain (DPNP) at the 7th Annual Meeting of the American Society of Pain and Neuroscience (ASPN 2025) - The Manila Times
Lexicon Pharmaceuticals to Present Study on Diabetic Peripheral Neuropathic Pain at ASPN 2025 Conference - Nasdaq
Revolutionary Non-Opioid Drug Could Help 100M People Suffering from Diabetic Nerve Pain - Stock Titan
What makes Lexicon Pharmaceuticals Inc. stock price move sharplyTop ROI Selections - beatles.ru
Lexicon Pharmaceuticals, Inc.'s (NASDAQ:LXRX) market cap touched US$389m last week, benefiting both private equity firms who own 48% as well as institutions - simplywall.st
Lexicon Pharmaceuticals (LXRX) Soars 16.74% on Technical Signals - AInvest
Lexicon Pharmaceuticals Defies Expectations: What Lies Ahead? - StocksToTrade
Lexicon Pharmaceuticals Granted Nasdaq Compliance Extension - The Globe and Mail
Lexicon Pharmaceuticals receives additional compliance period from Nasdaq - Investing.com
LEAD PLAINTIFF DEADLINE ALERT: Faruqi & Faruqi, LLP Encourages Investors Who Suffered Losses Exceeding $50,000 Investing In Lexicon Pharmaceuticals, Inc. To Contact The Firm - ACCESS Newswire
While institutions own 28% of Lexicon Pharmaceuticals, Inc. (NASDAQ:LXRX), private equity firms are its largest shareholders with 48% ownership - Yahoo Finance
HC Wainwright Reaffirms Buy Rating for Lexicon Pharmaceuticals (NASDAQ:LXRX) - MarketBeat
Congestive Heart Failure Market to Expand Significantly by 2034, States DelveInsight Report | Mesoblast, Bayer, Novo Nordisk, Lexicon Pharmaceuticals, Merck Sharp & Dohme LLC, Corthera - Barchart.com
Lexicon Pharmaceuticals (LXRX) Receives Buy Rating from HC Wainwright & Co. | LXRX Stock News - GuruFocus
H.C. Wainwright reiterates buy rating on Lexicon Pharmaceuticals stock By Investing.com - Investing.com Canada
Breakthrough: Sotagliflozin Cuts Dangerous Low Blood Sugar Events in Type 1 Diabetes Patients - Stock Titan
Lexicon to Present Data at the 85th Scientific Sessions of the American Diabetes Association (ADA) | LXRX Stock News - GuruFocus
Lexicon to Present Data at the 85th Scientific Sessions of the American Diabetes Association (ADA) - TradingView
New Clinical Data Shows Lexicon's Diabetes Drug Effective Across All Kidney Function LevelsADA Conference - Stock Titan
Revenues Not Telling The Story For Lexicon Pharmaceuticals, Inc. (NASDAQ:LXRX) After Shares Rise 31% - simplywall.st
Novo signs $812 million weight-loss drug license deal with US biotech Deep Apple - MarketScreener
Lexicon Pharmaceuticals surges 67% following InvestingPro’s Fair Value signal By Investing.com - Investing.com
Lexicon Pharmaceuticals at Jefferies Conference: Strategic Partnerships and Pipeline Progress - Investing.com Canada
Earnings call transcript: Lexicon Pharmaceuticals Q4 2024 beats EPS forecast By Investing.com - Investing.com UK
Lexicon Pharmaceuticals, Inc. (NASDAQ:LXRX) Shares Bought by Northern Trust Corp - Defense World
Lexicon Pharmaceuticals to Present at the 2025 Jefferies Global Healthcare Conference - The Manila Times
Lexicon Pharmaceuticals, Inc. (LXRX): Analysts See 285% Upside Potential - MSN
Lexicon Pharmaceuticals' Q1 2025: Unpacking Contradictions in Trial Designs, FDA Strategies, and Partnership Plans - AInvest
Lexicon (LXRX) Advances Study on Sotagliflozin for Heart Conditions | LXRX Stock News - GuruFocus
LXRXLexicon Pharmaceuticals Inc Latest Stock News & Market Updates - Stock Titan
Analysts Just Made A Noticeable Upgrade To Their Lexicon Pharmaceuticals, Inc. (NASDAQ:LXRX) Forecasts - simplywall.st
Earnings Update: Lexicon Pharmaceuticals, Inc. (NASDAQ:LXRX) Just Reported And Analysts Are Boosting Their Estimates - simplywall.st
Lexicon Pharmaceuticals, Inc. (NASDAQ:LXRX) Reported Earnings Last Week And Analysts Are Already Upgrading Their Estimates - Yahoo Finance
Lexicon targets late 2025 Phase 3 start for pilavapadin and expands LX9851 partnership with Novo Nordisk - MSN
Lexicon Pharmaceuticals, Inc. (NASDAQ:LXRX) Q1 2025 Earnings Call Transcript - Insider Monkey
4.91%
0.25%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):